The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Ten Common Questions (and Their Answers) About Off-label Drug Use
Open accessAbstract
The term off-label drug use (OLDU) is used extensively in the medical literature, continuing medical education exercises, and the media. Yet, we propose that many health care professionals have an underappreciation of its definition, prevalence, and implications. This article introduces and answers 10 questions regarding OLDU in an effort to clarify the practice's meaning, breadth of application, acceptance, and liabilities. Off-label drug use involves prescribing medications for indications, or using a dosage or dosage form, that have not been approved by the US Food and Drug Administration. Since the Food and Drug Administration does not regulate the practice of medicine, OLDU has become common. It occurs in every specialty of medicine, but it may be more common in areas of medicine in which the patient population is less likely to be included in clinical trials (eg, pediatric, pregnant, or psychiatric patients). Pharmaceutical companies are not allowed to promote their medications for an off-label use, which has lead to several large settlements for illegal marketing. To limit liability, physicians should prescribe medications only for indications that they believe are in the best interest of the patient. In addition, health care professionals should educate themselves about OLDU to weigh the risks and benefits and provide the best possible care for their patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“physicians may treat off-label clinical conditions and diseases for patients that respond poorly to conventional treatment, often in specific populations poorly represented in clinical trials, e.g. pediatric, pregnant or psychiatric patients (16).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [16]
In the citing paper
“Using pharmaceutical formulations (e.g. oral solution instead of capsules) or dosage (e.g. two tablets instead of one per day) not mentioned in the drug label for an indication also falls into the practice of off-label drug use (16).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., O'connor, A., Audette, J. F., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., Lebel, A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,342
Consensus Guidelines for Managing Postoperative Nausea and Vomiting
Gan, T. J., Meyer, T. A., Apfel, C. C., Chung, F. F., Davis, P. J., Eubanks, S., Kovac, A. L., Philip, B. K., Sessler, D. I., Temo, J., et al. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000068580.00245.95 · Cited by 964
The ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838
Off-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711
Liebowitz, M. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790300097013 · Cited by 576
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Pharmacologic Closure of Patent Ductus Arteriosus in the Premature Infant
Friedman, W. F., Hirschklau, M. J., Printz, M. P., Pitlick, P. T., & Kirkpatrick, S. E. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609022951003 · Cited by 497
Nightingale, S. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-3461-4.15001-9 · Cited by 444
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A. J., Moloney, R., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 426
Regulating Off-Label Drug Use — Rethinking the Role of the FDA
Stafford, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0802107 · Cited by 350
Research works printed but not linked: 2
- Qureshi, 2011, Enforcement actions involving Medicaid fraud and abuse, 1996-2009, Arch Intern Med, 171, 785
- Thomas, 2012, Glaxo agrees to pay $3 billion in fraud settlement, New York Times
Cited by
Sorted by citations
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 382
The High Cost of Cancer Drugs and What We Can Do About It
Siddiqui, M. A., & Rajkumar, S. V. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.007 · Cited by 264
Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018
Stark, A., Smith, P. B., Hornik, C. P. V., Zimmerman, K. O., Hornik, C. D., Pradeep, S., Clark, R. H., Benjamin, D. K., Laughon, M. M., & Greenberg, R. G. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.08.075 · Cited by 153
Nestler-Parr, S., Korchagina, D., Toumi, M., Pashos, C. L., Blanchette, C., Molsen, E., Morel, T., Simoens, S., Kaló, Z., Gatermann, R., et al. (2018) · Value in Health · doi:10.1016/j.jval.2018.03.004 · Cited by 131
Metadata
- Authors
- Wittich, C. M., Burkle, C. M., & Lanier, W. L.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Wittich, Christopher M.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 87
- Issue
- 10
- Pages
- 982-990
- ISSN
- 0025-6196 (ISSN-L)
- PMC
- PMC3538391
- OpenAlex
- W2166119767
- Cited by
- 368
- References
- 48
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 62 · 2023: 42 · 2022: 32 · 2021: 35 · 2020: 26 · 2019: 29 · 2018: 25 · 2017: 25 · 2016: 21 · 2015: 11 · 2014: 12 · 2013: 4 · 2012: 3
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Mayo Clinic Proceedings (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- off-label drug use, FDA-approved indications, prescribing patterns, physician liability, pharmaceutical marketing, pediatric prescribing, pregnant patients, psychiatric patients, risk-benefit assessment
- MeSH terms
- Attitude of Health Personnel, Drug Labeling, Female, Humans, Male, Patient Education as Topic, Physician-Patient Relations, Practice Patterns, Physicians', Drug Prescriptions, United States, United States Food and Drug Administration, Safety Management, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
